US Patent 9,084,778: Scope, Claim Construction, Expiration Risk, and Trifarotene Patent Landscape

US Patent 9,084,778 protects topical pharmaceutical compositions containing trifarotene, particularly water-in-oil emulsions that combine an oily phase, a solvent system, a co-solvent oil, and a gelled aqueous phase. The strongest commercial coverage is directed to trifarotene formulations containing phenoxyethanol or specified oils, with or without a separate emulsifier. The patent also includes pharmacokinetic performance limitations and broad dermatological treatment methods.

The patent is formulation-focused rather than a basic compound patent. Its principal competitive value is therefore in blocking or complicating alternative topical formulations of trifarotene, especially products designed to reproduce the claimed dermal and epidermal absorption profile.

What does US Patent 9,084,778 cover?

US Patent 9,084,778 covers pharmaceutical compositions containing a defined class of substituted terphenyl compounds, with claim 3 identifying the active ingredient as trifarotene:

3''-tert-butyl-4'-(2-hydroxyethoxy)-4''-pyrrolidin-1-yl-[1,1':3',1''-terphenyl]-4-carboxylic acid.

Trifarotene is a selective retinoic acid receptor gamma agonist used topically for acne vulgaris and facial and truncal acne. The FDA approved trifarotene cream under the brand name Aklief in 2019. [1]

The independent composition claim requires all of the following:

Required element	Claim scope
Active compound	Formula I genus, including trifarotene
Oily phase	Must contain the compound, a principal solvent, and a co-solvent oil
Aqueous phase	Must contain at least one gelling agent
Emulsion architecture	Broadly covers compositions with separate oily and aqueous phases
Emulsifier	Claim 4 excludes a separate emulsifying agent
Product type	Claim 15 narrows the composition to a water-in-oil emulsion

The claim is therefore not limited to a particular commercial brand, container, concentration, or indication. It is directed to the formulation architecture and ingredient relationships.

What compound does US 9,084,778 protect?

Claim 3 expressly identifies trifarotene, while claim 1 covers a broader chemical genus.

The formula I genus includes variation in:

Substituents R1, R2, and R3 on the aromatic rings.
N-substitution through R4 and R5.
Pyrrolidine, pyrrolidinone, piperidine, and piperidinone ring structures.
Oxygen-linked or carbon-linked substituents at X.
Side-chain structures represented by A.
Heteroatoms represented by Y, including oxygen and sulfur under claim 21.
Phenyl, pyridyl, and thiophenyl aromatic systems.

The genus is materially broader than trifarotene. A competing product containing a different compound within the formula could potentially fall within claim 1 if its formulation also satisfies the solvent, oil, and aqueous-gel requirements.

Claim 3 is commercially more important because it isolates trifarotene. Claims 46 through 73 replicate many of the formulation limitations applicable to claim 3 and provide narrower dependent coverage.

How strong is the independent composition claim?

Claim 1 has meaningful breadth but also contains multiple cumulative limitations. An accused formulation must satisfy each required element.

Strengths

The claim does not require:

A specific therapeutic indication.
A particular dosage strength.
A named commercial excipient.
A particular manufacturing process.
A specific particle size or crystal form.
A particular package or delivery device.

The principal solvent and co-solvent oil are defined functionally and through Markush lists. This gives the claim potential reach across multiple topical formulation designs.

The claim also supports infringement theories against formulations that use different trade-name excipients but chemically equivalent materials. For example, a formulation using a carbomer other than Carbopol 980 could remain within the broad “gelifying agent” limitation.

Limitations

The composition must include:

An oily phase.
A principal solvent for the active compound.
A co-solvent oil.
An aqueous phase containing a gelling agent.

A simple anhydrous oil, hydroalcoholic solution, conventional oil-in-water cream, or polymeric gel may avoid claim 1 if it lacks the required phase structure.

The claim also requires that the oily phase contain the active compound. A product in which trifarotene is held primarily in the aqueous phase could create a non-infringement position, subject to the factual formulation and claim construction.

What formulations are protected by US 9,084,778?

Claims 5 through 13 and 22 through 34 identify specific classes of excipients.

Principal solvents

Claim 6 lists:

Benzyl alcohol
Laureth-4
Phenoxyethanol
Propylene glycol monocaprylate
Pentylene glycol
Dimethyl isosorbide

Claim 7 narrows the formulation to phenoxyethanol. A formulation containing trifarotene, phenoxyethanol, an oil, and a gelling agent is a direct target for claim analysis.

Co-solvent oils

Claim 8 lists:

Caprylic/capric triglycerides
Sweet almond oil
Propylene glycol monocaprylate
Propylene glycol laurate
Sorbitan sesquioleate
Diisopropyl adipate
PPG-15 stearyl ether
Apricot kernel oil PEG-6 ester

The list includes both conventional cosmetic oils and ester-based solvent materials. This reduces the ability of a follow-on manufacturer to avoid the patent merely by changing the oil within the listed class.

Gelling agents

Claim 5 and its dependent claims cover:

Pemulen TR-1 and Pemulen TR-2
Sepigel 305
Carbopol and Ultrez carbomers
Xanthan and gellan gums
Guar gum
Cellulose polysaccharides
Aluminum magnesium silicates
Hydrophobically modified acrylic polymers
Modified starches
Carrageenans
Simulgel 600 PHA
Avicel CL-611
Veegum K
Aculyn 44
Structure Solance

The excipient claims are drafted as alternatives. They do not require every listed gelling agent. A formulation using one listed agent may satisfy the relevant dependent claim even if it does not use the commercial product named in the specification.

What concentration ranges are protected?

Claim 14 establishes a broad quantitative formulation profile:

Component	Broad claimed range
Trifarotene	0.00001% to 1% w/w
Aqueous-phase gelling agent	0.005% to 10% w/w
Principal solvent	0.2% to 5% w/w
Co-solvent oil	0.5% to 50% w/w
Mineral oil	0% to 20% w/w
Polyol	0% to 50% w/w
Silicone oil	0% to 10% w/w
Preservative system	0% to 5% w/w
Ethanol	0% to 30% w/w
Other additives	0% to 15% w/w

Claims 35 through 45 narrow these ranges. The most commercially relevant subranges include:

Trifarotene at 0.0001% to 0.1% w/w.
Gelifying agent at 1% to 5% w/w.
Principal solvent at 0.5% to 2% w/w.
Co-solvent oil at 4% to 30% w/w.
Polyol at 5% to 35% w/w.
Preservative system at 0.01% to 2% w/w.

A formulation does not necessarily avoid the patent because one ingredient falls outside a dependent range. The broader independent claim may remain relevant if the general phase and solvent limitations are met.

Do the absorption claims create separate infringement risk?

Claims 16 through 18 add pharmacokinetic limitations.

They cover compositions in which:

The maximum quantity absorbed in the dermis and epidermis 16 hours after application is between 6 ng/cm² and 19 ng/cm².
A narrower range is 6.8 ng/cm² to 10.6 ng/cm².
Maximum epidermal absorption occurs between three and 10 hours after application.

These are formulation-performance claims. They can be valuable when a product has a similar composition but uses different excipient names or concentrations.

Their enforcement value is more complex than that of ingredient claims. Infringement may require analytical testing of the accused product under comparable application, sampling, and measurement conditions. Differences in dose, skin model, application site, occlusion, sampling technique, or analytical method could affect the result.

What method-of-use claims does US 9,084,778 contain?

Claim 20 covers treatment of a broad range of dermatological conditions using the composition. Claim 60 repeats substantially the same method coverage for compositions according to claim 3.

The listed indications include:

Acne and rosacea.
Keratinization disorders.
Psoriasis, eczema, and atopic dermatitis.
Photoaging and chronological aging.
Pigmentation disorders.
Actinic keratoses.
Warts and viral epidermal proliferations.
Lupus and immune-mediated skin disease.
Cutaneous atrophy and scarring.
Fungal disorders.
Pre-cancerous and cancerous skin conditions.

The method claims are substantially broader than the FDA-approved Aklief indication. The FDA label identifies topical trifarotene for acne vulgaris in patients aged nine years and older, including facial and truncal acne. [1]

A method claim directed to an unapproved condition may still have patent value, but commercial enforcement depends on labeling, promotional conduct, physician prescribing patterns, and induced-infringement evidence. The broad list also creates potential written-description and enablement pressure for disease areas not supported by meaningful clinical data.

When does US 9,084,778 lose exclusivity?

The patent was granted on July 21, 2015. Its nominal expiration is expected to fall in the late 2020s, generally based on the earliest effective nonprovisional filing date and adjusted for any patent-term adjustment or terminal disclaimer. A precise expiration date requires confirmation from the USPTO patent-term record and the complete priority chain. [2]

The relevant commercial exclusivity analysis has three separate components:

Exclusivity layer	Relevance
Compound patent protection	May be separate from US 9,084,778 and may expire on a different date
Formulation patent protection	US 9,084,778 is directed principally to this layer
FDA regulatory exclusivity	Separate from patent term and tied to the approved product and indication

For Aklief, the formulation patent may not be the only barrier to an ANDA. Other listed Orange Book patents, later continuation patents, method patents, or unlisted patent rights could affect generic entry. The Orange Book must be reviewed by patent number and product listing rather than by assuming that one patent defines the entire exclusivity position. [3]

What is the Orange Book status of trifarotene?

Aklief is an FDA-approved prescription topical cream containing trifarotene. FDA approval occurred in October 2019. [1]

Trifarotene is a small molecule, not a biologic. A follow-on applicant would normally use the abbreviated new drug application pathway rather than a biosimilar pathway. Biosimilar litigation under the Public Health Service Act is not the relevant framework.

The Orange Book analysis should focus on:

Whether US 9,084,778 is listed against the relevant Aklief presentation.
Any later patent listings for formulation, use, or delivery.
The expiration dates reported for each listed patent.
Whether a generic applicant has submitted a Paragraph IV certification.
Whether FDA has accepted or approved any ANDA referencing Aklief.

Patent listing and litigation are separate issues. An Orange Book listing does not establish validity, enforceability, or infringement.

Which companies are challenging trifarotene exclusivity?

The principal commercial holder associated with trifarotene is Galderma. Aklief is marketed by Galderma Laboratories, L.P. [1]

No biosimilar competitor is expected because trifarotene is a synthetic small molecule. The practical competitors are:

Generic topical trifarotene manufacturers.
Companies developing alternative acne retinoids.
Products containing adapalene.
Products containing tretinoin.
Products containing tazarotene.
Non-retinoid acne therapies such as clascoterone or benzoyl peroxide combinations.

A Paragraph IV challenge would likely attack one or more of the following:

Anticipation by an earlier topical retinoid formulation.
Obviousness based on known retinoid vehicles and emulsion systems.
Lack of written description for the large formula I genus.
Lack of enablement across the full disease and formulation scope.
Indefiniteness in functional absorption limitations.
Non-infringement based on a formulation outside the required phase architecture.

No specific Paragraph IV challenger or settlement should be inferred from the patent claims alone. Those facts require current FDA and federal court records.

How does US 9,084,778 compare with competing retinoid patent estates?

Product	Active ingredient	Product type	Competitive patent focus
Aklief	Trifarotene	Topical cream	Trifarotene formulation, use, and delivery
Differin	Adapalene	Gel, cream, lotion	Compound and formulation history; many products now generic
Retin-A	Tretinoin	Cream, gel, microsphere products	Compound largely mature; formulation and delivery vary
Tazorac	Tazarotene	Cream, gel, foam	Compound, prodrug, formulation, and use patents
Winlevi	Clascoterone	Topical cream	Newer composition and method claims

US 9,084,778 is narrower than a compound patent but potentially stronger against a close formulation copy. Its practical value increases when a competitor uses trifarotene with an oily solvent phase, phenoxyethanol, a listed co-solvent oil, and an aqueous gelling agent.

What manufacturing and formulation barriers does the patent create?

The patent creates several design-around constraints:

Trifarotene must be solubilized without reproducing the claimed principal-solvent and oil combination.
The product may need to avoid a separate aqueous gel phase.
An oil-in-water architecture may be preferable to a water-in-oil emulsion, subject to the scope of claim 1.
A non-listed solvent system may reduce literal infringement exposure.
A formulation could use a different polymer or anhydrous vehicle, although the broad “gelifying agent” language requires careful construction.
Absorption-performance claims require separate testing because a composition outside a listed ingredient combination could still produce the claimed dermal exposure profile.

The highest-risk product profile is a trifarotene water-in-oil cream using phenoxyethanol, caprylic/capric triglycerides or another listed oil, and a listed aqueous gelling agent.

Key Takeaways

US 9,084,778 is a trifarotene formulation patent, not merely a compound patent.
Claim 1 requires an oily phase, principal solvent, co-solvent oil, and gelled aqueous phase.
Claim 3 specifically targets trifarotene.
Claims 5 through 13 and 22 through 34 cover extensive excipient alternatives.
Claims 14 and 35 through 45 protect concentration ranges.
Claims 16 through 18 protect specified dermal and epidermal absorption outcomes.
Claims 20 and 60 cover broad dermatological treatment methods beyond the approved acne indication.
A generic trifarotene product would face small-molecule ANDA and Paragraph IV issues, not biosimilar litigation.
The nominal patent term is expected to extend into the late 2020s, subject to the USPTO term calculation.
The strongest infringement risk concerns close water-in-oil trifarotene formulations using phenoxyethanol, listed oils, and listed aqueous gelling agents.

FAQs About US Patent 9,084,778

Is US 9,084,778 a patent on Aklief itself?

No. It is principally a formulation and method patent. Trifarotene is expressly recited in claim 3, but the patent does not represent the entire global patent estate for Aklief.

Can a generic avoid US 9,084,778 by using a different brand-name excipient?

Not necessarily. The claims are directed to chemical and functional categories, not only trade names. A chemically equivalent substitute may still fall within a broader claim.

Does an oil-in-water trifarotene cream avoid the patent?

It may reduce risk under claim 15, which expressly requires a water-in-oil emulsion. It does not automatically avoid claim 1 because the construction of the oily and aqueous phases remains material.

Are the broad disease-treatment claims likely to block an acne generic?

The acne indication is the most commercially relevant method-of-use category. A generic applicant could contest the claims through certification, labeling strategy, or a non-infringing label, depending on the patents listed against the reference product.

Is there a biosimilar pathway for trifarotene?

No. Trifarotene is a synthetic small molecule. A follow-on product would generally be submitted as an ANDA, with patent certifications governed by the Hatch-Waxman framework.

References

U.S. Food and Drug Administration. (2019). Aklief (trifarotene) cream prescribing information.
United States Patent and Trademark Office. (2015). U.S. Patent No. 9,084,778, pharmaceutical composition comprising a retinoid.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th ed.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Galderma Labs Lp	AKLIEF	trifarotene	CREAM;TOPICAL	211527-001	Oct 4, 2019		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial	Y			TREATMENT OF ACNE VULGARIS	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2013269583	⤷ Start Trial
Brazil	112014029885	⤷ Start Trial
Canada	2874474	⤷ Start Trial
Chile	2014003226	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 9,084,778

Which drugs does patent 9,084,778 protect, and when does it expire?

Summary for Patent: 9,084,778